MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Collaborative Practice Authority
20 questions · exam conditions
0:00
Collaborative Practice AuthorityQuestion 1 of 20

Which of the following is the primary legal basis for a pharmacist's authority to perform drug therapy management activities under a CPA?

State law -- specifically an enabling statute in the state pharmacy practice act or related legislation that authorizes CPAs and defines what they may contain.
A national standard established by ASHP that applies uniformly in all states.
DEA approval, which authorizes pharmacists to manage drug therapy under physician oversight.
A voluntary agreement between the pharmacist and the physician, which creates authority without requiring a specific state enabling statute.
← Back to quizzes

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Collaborative Practice Authority

Practice Collaborative Practice Authority in MPJE: Multistate Pharmacy Jurisprudence Examination with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Collaborative Practice Authority, giving you a quick way to practice the rules, question types, and explanations that matter most for MPJE: Multistate Pharmacy Jurisprudence Examination.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

Which of the following is the primary legal basis for a pharmacist's authority to perform drug therapy management activities under a CPA?

  1. State law -- specifically an enabling statute in the state pharmacy practice act or related legislation that authorizes CPAs and defines what they may contain. (correct answer)
  2. A national standard established by ASHP that applies uniformly in all states.
  3. DEA approval, which authorizes pharmacists to manage drug therapy under physician oversight.
  4. A voluntary agreement between the pharmacist and the physician, which creates authority without requiring a specific state enabling statute.
Explanation: CPA authority derives from state enabling statutes. Without a state law authorizing CPAs and defining their permissible scope, a CPA between a pharmacist and physician has no legal force to expand pharmacy practice. The enabling statute establishes the outer limits of what a CPA may authorize. B is incorrect because ASHP is a professional organization; its standards do not create legal authority. C is incorrect because DEA approval is not required for or relevant to CPAs for non-controlled drug therapy management. D is incorrect because a private agreement between practitioners cannot create legal authority in the absence of an enabling state statute.

Question 2

In a state whose CPA enabling statute authorizes pharmacists to initiate and manage drug therapy for specified conditions under physician supervision, a CPA between a pharmacist and an addiction medicine physician authorizes the pharmacist to initiate and manage buprenorphine-based medication-assisted treatment for opioid use disorder. Which of the following best describes an additional federal consideration the pharmacist must understand?

  1. The pharmacist must obtain a separate state prescribing license because buprenorphine management requires independent prescriptive authority.
  2. The pharmacist must obtain individual FDA approval for the buprenorphine product used under the CPA.
  3. The collaborating physician must have a DEA registration for Schedule III drugs to prescribe buprenorphine. (correct answer)
  4. No additional federal requirements apply because the CPA provides all necessary authority.
Explanation: Buprenorphine for opioid use disorder is a Schedule III controlled substance. The Consolidated Appropriations Act of 2023 eliminated the DATA 2000 X-waiver requirement, so any DEA-registered practitioner authorized to prescribe Schedule III substances may now prescribe buprenorphine for OUD. A pharmacist managing buprenorphine under a CPA does so within the collaborating physician's DEA-based prescribing authority -- the CPA extends authorized drug therapy management activities to the pharmacist but does not independently create pharmacist prescribing authority. The physician's current DEA registration is therefore a critical federal prerequisite that the pharmacist must verify. A is incorrect because the question addresses federal requirements; in this jurisdiction the state CPA authority is established and a separate state prescribing license is not what is at issue. B is incorrect because FDA product approval is a manufacturer-level requirement, not a practitioner-level requirement. D is incorrect because a CPA addresses state law authority but does not satisfy federal DEA requirements governing the physician's controlled substance prescribing authority.

Question 3

A CPA specifies that it covers patients with type 2 diabetes managed in the primary care clinic. A patient managing his type 2 diabetes independently with OTC products -- and who is not an established patient of the clinic -- approaches the pharmacist at the clinic requesting help adjusting his insulin. Which of the following best applies?

  1. The pharmacist may not act under the CPA as the patient is not an established clinic patient. (correct answer)
  2. The pharmacist may act under the CPA because the patient has type 2 diabetes, which matches the condition specified.
  3. The pharmacist may act because the condition is diabetes and the pharmacist has clinical expertise in diabetes management.
  4. The pharmacist may act under the CPA for this visit only, after which the patient must establish care with the physician.
Explanation: The CPA defines a specific patient population: patients with type 2 diabetes managed in the primary care clinic. A non-established patient managing his condition independently does not fall within this defined population. Acting on a patient outside the defined scope exceeds the CPA's authority. B is incorrect because matching the diagnosis alone is insufficient; the patient must also fit the patient population definition. C is incorrect because clinical expertise does not expand CPA scope beyond its defined patient population. D is incorrect because the CPA does not include a provision for one-time exceptions; the patient population definition must be met.

Question 4

A CPA authorizes a pharmacist to substitute within a defined formulary of beta-blockers for patients with heart failure. Due to a shortage, the pharmacist switches a patient from metoprolol succinate to carvedilol, both of which are on the formulary. No prior physician consultation occurs. Which of the following best applies?

  1. This exceeds the CPA's scope because any drug change requires physician approval under federal law.
  2. This exceeds the CPA's scope because formulary substitution always requires a new prescription.
  3. This is within scope only if both drugs belong to the same therapeutic subclass.
  4. This is within the CPA's scope if the switch is documented and appropriate for the patient's condition. (correct answer)
Explanation: The CPA specifically authorizes formulary substitutions within the defined beta-blocker formulary for heart failure patients. Switching from metoprolol succinate to carvedilol -- both on the formulary -- for a heart failure patient is exactly the type of substitution the CPA authorizes. Requiring physician consultation for each change would defeat the purpose of the CPA. The pharmacist must document the change per CPA requirements. A is incorrect because there is no federal law requiring physician approval for every CPA-authorized formulary change. B is incorrect because CPAs are designed to authorize certain changes without requiring a new prescription for each; that is a core function. C is incorrect because both agents are beta-blockers on the defined formulary; this condition is satisfied.

Question 5

A state's CPA enabling statute requires that the supervising physician be available for consultation when the pharmacist performs drug therapy management activities. A pharmacist performs anticoagulation management while her supervising physician is traveling internationally and is completely unreachable. Which of the following best applies?

  1. This is permissible because the physician's physical location is irrelevant as long as the CPA document is signed.
  2. This is permissible because available for consultation means available during normal business hours, not necessarily immediately reachable.
  3. This is non-compliant; the pharmacist must ensure the supervising physician is reachable for consultation during drug therapy management activities. (correct answer)
  4. This is permissible as long as the physician has pre-approved a specific protocol for the pharmacist to follow in his absence.
Explanation: If state law requires physician availability for consultation during CPA activities, performing those activities when the physician is completely unreachable may violate the CPA's conditions. The CPA should address backup consultation arrangements. A is incorrect because physician availability for consultation is a statutory condition, not merely a formality satisfied by a signed document. B is incorrect because complete international unreachability is a more fundamental availability failure than simple off-hours unavailability. D is incorrect because pre-approved protocols alone may not satisfy an availability requirement if the statute requires actual real-time access for consultation.

Question 6

A pharmacist has operated under a CPA with a cardiologist for two years and has developed clinical expertise beyond what the CPA originally contemplated. She begins making clinical decisions not explicitly authorized by the CPA's terms, reasoning that her demonstrated competency justifies these activities. Which of the following best analyzes her position?

  1. The pharmacist is acting outside her authority; CPA scope is defined by its written terms, not personal expertise. (correct answer)
  2. The pharmacist is acting within her authority because demonstrated clinical competency is the governing standard for CPA scope.
  3. The pharmacist is acting within her authority because the cardiologist's implied ongoing approval covers expanded clinical judgment.
  4. The pharmacist may expand her activities as long as she documents her reasoning in the patient's medical record.
Explanation: Clinical competency does not equal legal permission -- this is the core CPA distractor pattern. The CPA's written terms define the legal scope of the pharmacist's authority. Expanded expertise may justify formally amending the CPA to include new activities, but it does not by itself authorize activities not in the agreement. B is incorrect because clinical competency is a qualification standard, not the legal authority standard. C is incorrect because implied ongoing approval from the physician does not expand a CPA's written scope; the agreement must be amended in writing. D is incorrect because documentation of reasoning does not create authority for activities outside the CPA's terms.

Question 7

A pharmacist practicing under a CPA for drug therapy management identifies a patient experiencing a significant adverse drug reaction to a medication within the CPA's scope. The CPA does not explicitly address medication discontinuation. Which of the following best describes the pharmacist's required course of action?

  1. The pharmacist may discontinue the medication because adverse drug reaction management is implied by any drug therapy management authority.
  2. The pharmacist must contact the prescriber to report the reaction and obtain authorization to discontinue the medication, as the CPA does not explicitly permit unilateral action. (correct answer)
  3. The pharmacist may discontinue the medication because preventing patient harm always overrides CPA scope limitations.
  4. The pharmacist may not take any action because the CPA does not authorize discontinuation and the pharmacist must wait for the patient's next scheduled appointment.
Explanation: When a CPA does not explicitly authorize a specific activity such as medication discontinuation, the pharmacist should not act unilaterally based on implied authority. The appropriate course is to contact the prescriber immediately, report the adverse reaction, and obtain an explicit order to discontinue. This ensures the action is taken within the CPA's collaborative framework and maintains the prescriber's role in authorizing activities the agreement does not expressly address. A is incorrect because implied authority is not a sufficient basis for acting outside the CPA's express terms; the prescriber must be engaged to authorize the specific activity. C is incorrect because while patient safety is a compelling concern, it does not automatically expand the pharmacist's CPA scope; the prescriber must be involved except in a true life-threatening emergency requiring immediate action. D is incorrect as an absolute rule because waiting for a scheduled appointment in the face of a significant adverse reaction would be clinically inappropriate; the prescriber must be contacted immediately.

Question 8

A pharmacist has 15 years of complex diabetes management experience. A patient's new primary care physician who is not the CPA collaborating physician tells the pharmacist to keep doing what she has been doing with the patient's diabetes. No new CPA has been executed with this physician. Which of the following best analyzes whether the pharmacist may continue managing this patient's diabetes?

  1. The pharmacist may continue because the new physician's verbal authorization is sufficient to maintain established clinical activities.
  2. The pharmacist may continue because the prior CPA covers the patient's established care plan even though the collaborating physician has changed.
  3. The pharmacist may not continue without a written CPA with the new physician, as verbal authorization is insufficient. (correct answer)
  4. The pharmacist may continue for a 90-day transition period while a formal CPA with the new physician is established.
Explanation: This scenario presents two problems: the collaborating physician has changed, which may invalidate the original CPA if it was physician-specific, and the new physician's verbal instruction does not constitute a CPA. Clinical expertise and established care patterns do not create legal authority; the CPA's legal foundation depends on a valid written agreement with an authorized prescriber. A is incorrect because verbal authorization does not satisfy the written CPA requirement. B is incorrect because a CPA is tied to its specific parties; a change in the collaborating physician typically requires a new CPA. D is incorrect because a 90-day verbal-authorization transition period is not a recognized legal provision.

Question 9

A CPA states that the pharmacist may order laboratory tests necessary to monitor drug therapy. A physician asks the pharmacist to order an MRI for a patient because the pharmacist has an advanced clinical degree. Which of the following best applies?

  1. The pharmacist may order the MRI because the CPA grants broad clinical authority including diagnostic imaging.
  2. The pharmacist may not order the MRI because the CPA authorizes only laboratory tests necessary to monitor drug therapy; diagnostic imaging is not a laboratory test and exceeds the CPA's scope. (correct answer)
  3. The pharmacist may order the MRI because the physician's request overrides the CPA's specific language.
  4. The pharmacist may order the MRI because it is clinically necessary and the CPA allows any test the pharmacist deems appropriate.
Explanation: The CPA's language specifically authorizes laboratory tests necessary to monitor drug therapy. An MRI is a diagnostic imaging study, not a laboratory test for drug therapy monitoring, and falls outside the CPA's specific authorization. A is incorrect because the CPA's authority is specific to laboratory tests for drug therapy monitoring, not all diagnostics. C is incorrect because the physician's verbal request does not expand the CPA's written scope; the agreement's terms govern. D is incorrect because the CPA does not grant open-ended authority to order any test the pharmacist deems appropriate.

Question 10

In a state whose CPA enabling statute specifically permits pharmacists to initiate drug therapy from a defined formulary, a CPA authorizes a pharmacist to initiate antihypertensive treatment for patients meeting defined clinical criteria. A new patient with stage 2 hypertension who has never been prescribed antihypertensives presents and meets all CPA criteria. The pharmacist selects amlodipine from the formulary and initiates therapy. Which of the following most accurately describes whether this is within scope?

  1. This is within the CPA's scope, provided the patient falls within the CPA's defined patient population and the pharmacist complies with all CPA conditions and protocols. (correct answer)
  2. This exceeds the CPA's scope because initiating therapy for a new patient requires a prior physician examination.
  3. This is within scope only if the pharmacist also holds independent prescriptive authority under state law.
  4. This exceeds the CPA's scope because a CPA may only authorize adjustments to existing therapy, not initiation of new therapy.
Explanation: In a state that specifically enables CPAs to authorize pharmacists to initiate drug therapy, selecting an appropriate agent from the defined formulary for a new patient who meets all CPA criteria is within scope. Both the enabling statute and the CPA's terms must authorize initiation for the activity to be lawful, and here both conditions are met. B is incorrect because in a state authorizing CPA-based initiation, a prior physician examination is not a universal prerequisite; the CPA's defined criteria and protocols govern the required assessment. C is incorrect because CPA authority derives from the CPA and its enabling statute, not from independent prescriptive authority. D is incorrect because in states enabling CPA-based initiation, CPAs may authorize starting new therapy as well as making adjustments; the scope is defined by what the statute and agreement permit.

Question 11

A pharmacist practices in both an outpatient primary care clinic under a CPA and at a hospital where she works additional shifts. The CPA specifies it covers the outpatient clinic setting. During a hospital shift, she wants to apply the same drug therapy management protocols. Which of the following best applies?

  1. The pharmacist may apply the CPA protocols at the hospital because the same pharmacist-physician relationship underlies both settings.
  2. The CPA is limited to the outpatient clinic setting as specified; the pharmacist may not extend CPA authority to the hospital without a separate CPA for that setting. (correct answer)
  3. The pharmacist may apply the CPA at the hospital because the protocols were developed by the same physician.
  4. The pharmacist may apply the CPA at the hospital during a transition period until a hospital-specific CPA is established.
Explanation: CPAs are setting-specific when they so specify. A CPA covering the outpatient clinic does not automatically extend to the hospital. The pharmacist needs a separate CPA for the hospital, executed with authorized prescribers in that setting and compliant with that facility's policies and applicable state law. A is incorrect because the pharmacist-physician relationship is not sufficient to extend a CPA beyond its defined setting. C is incorrect because the protocol's origin does not override the CPA's setting specification. D is incorrect because a transition period does not create legal authority where none exists; a valid CPA must be in place before exercising CPA-level authority at the hospital.

Question 12

A state's CPA statute requires that patients be informed of and consent to pharmacist drug therapy management under a CPA. A pharmacist managing anticoagulation therapy for multiple patients has been adjusting medications without informing patients that a pharmacist, not their physician, is making the adjustments. Which of the following best analyzes the compliance concern?

  1. The pharmacist's practice violates compliance by not informing patients of their role in drug therapy management, breaching state law requiring patient notification and consent under CPA. (correct answer)
  2. There is no compliance concern because the CPA is between the pharmacist and physician, not the patient; patients are not parties to the agreement.
  3. There is no compliance concern because anticoagulation management is a recognized pharmacist service and patients implicitly consent by attending the clinic.
  4. The compliance concern is minor because the pharmacist's clinical outcomes were positive.
Explanation: When state law requires patient notification and consent for CPA-based care, failing to inform patients violates the statutory requirement and implicates their right to informed consent. Patients have the right to know who is managing their medications and under what authority. B is incorrect because while the CPA is executed between the pharmacist and physician, state law may impose patient notification requirements as a condition of CPA validity; patients have legal rights in this context. C is incorrect because implicit consent through clinic attendance does not satisfy an explicit statutory consent requirement. D is incorrect because positive outcomes do not retroactively satisfy procedural compliance obligations.

Question 13

A physician wants a CPA to authorize the pharmacist to diagnose new medical conditions and independently determine appropriate drug therapy for patients without any prior physician assessment. Which of the following best describes whether this is permissible?

  1. This is permissible because a physician may delegate any clinical function to a pharmacist under a CPA.
  2. This is permissible because a CPA between credentialed practitioners is self-governing.
  3. This is permissible if the pharmacist has completed a clinical doctorate program.
  4. This is not permissible; pharmacists cannot diagnose new conditions under a CPA. (correct answer)
Explanation: Two key limitations apply: state pharmacy law defines what pharmacists are authorized to do, and physicians cannot delegate authority that exceeds what they are permitted to delegate. Diagnosing new medical conditions falls within medical practice as defined by state law and is typically outside pharmacy scope of practice. A CPA cannot authorize activities beyond the enabling statute and state pharmacy practice act. A is incorrect because physician delegative authority has legal limits; physicians cannot expand pharmacy scope beyond state law. B is incorrect because CPAs must comply with state law limitations; they are not self-governing instruments. C is incorrect because a clinical doctorate changes qualifications but does not by itself change what pharmacists are legally authorized to do.

Question 14

A state enacted legislation creating an Advanced Practice Pharmacist (APh) designation granting qualifying pharmacists authority to perform drug therapy management functions without a CPA in specific settings. A pharmacist who holds the APh designation begins ordering laboratory tests and adjusting drug therapy in an outpatient clinic without a CPA. Which of the following best analyzes whether this is permissible?

  1. This is not permissible under any circumstances because drug therapy management always requires a CPA.
  2. This is permissible because the pharmacist holds relevant board certification.
  3. This is permissible if the APh designation covers these activities and settings under state law. (correct answer)
  4. This is permissible because the physician-CPA requirement is a federal regulation that the state APh designation preempts.
Explanation: The permissibility depends on the specific scope defined by the state APh statute. Some states granting APh designations specifically authorize those pharmacists to perform certain activities without a CPA in defined settings. Other states still require a CPA even for APh-designated pharmacists. The pharmacist must carefully review the state's APh statute provisions. A is incorrect because some state APh designations specifically authorize drug therapy management without a CPA. B is incorrect because board certification is a qualification, not the source of legal authority. D is incorrect because CPA requirements are state law matters, not federal regulations, so there is nothing to preempt.

Question 15

A pharmacist practices under a CPA in State A and also holds a pharmacist license in State B. A patient from State A moves to State B and wants to continue receiving drug therapy management from the same pharmacist. Which of the following best analyzes whether the State A CPA applies in State B?

  1. The CPA applies in State B because it was validly executed in State A and interstate recognition of healthcare agreements is standard practice.
  2. The CPA applies in State B because the pharmacist holds a license in both states.
  3. The CPA applies in State B because the patient-pharmacist relationship transcends state lines.
  4. The CPA does not apply in State B; it must comply with State B's laws to be valid there. (correct answer)
Explanation: CPAs are state-law instruments that derive their authority from the enabling statute of the state in which they are executed. A CPA authorized under State A law has no legal effect in State B. The pharmacist would need to execute a new CPA complying with State B's requirements with a physician authorized in State B. A is incorrect because interstate recognition of healthcare agreements is not automatic; state-specific legal frameworks apply. B is incorrect because holding a license in both states does not create CPA authority in both states; the CPA itself must comply with each state's law. C is incorrect because patient-pharmacist relationships do not create jurisdiction-transcending legal authority.

Question 16

A CPA requires the pharmacist to document all drug therapy management activities in the patient's medical record within 24 hours of each encounter. The pharmacist manages a patient's anticoagulation on Friday afternoon but does not complete the documentation until Monday morning. Which of the following best describes the compliance concern?

  1. There is no compliance concern because the documentation was completed before the next scheduled patient visit.
  2. There is no compliance concern because medical record documentation timelines are aspirational, not enforceable.
  3. The pharmacist violated the 24-hour documentation requirement, resulting in non-compliance with the CPA agreement. (correct answer)
  4. The pharmacist has complied because weekends are excluded from documentation timelines under standard healthcare practice.
Explanation: The CPA imposes a specific 24-hour documentation obligation. Performing the activity Friday afternoon and documenting Monday morning exceeds 24 hours. This is a compliance violation independent of patient outcome. Documentation serves both a clinical purpose and a legal purpose as evidence of acting within scope. A is incorrect because compliance is measured against the 24-hour requirement, not against the next visit schedule. B is incorrect because CPA documentation requirements are enforceable terms, not aspirational guidance. D is incorrect because the CPA specifies 24 hours without a weekend exclusion; absent such a provision, the 24-hour period runs regardless of day.

Question 17

A pharmacist's CPA is terminated when the collaborating physician leaves the practice. The pharmacist continues to perform drug therapy management activities for established patients, believing continuity of care justifies temporary continuation. Which of the following best describes the pharmacist's compliance status?

  1. The pharmacist is non-compliant; drug therapy management requires an active CPA with an authorized prescriber. (correct answer)
  2. The pharmacist may continue for up to 30 days to ensure continuity of care for established patients.
  3. The pharmacist may continue because established clinical relationships with patients create an implied continuation of CPA authority.
  4. The pharmacist may continue as long as she documents her actions and notifies the state board within 14 days.
Explanation: A CPA's authority depends on having an active agreement with an authorized prescriber. When the CPA terminates, the pharmacist's authority under it ends immediately. Continuing to perform CPA-authorized activities without a valid CPA is practicing beyond the legal scope of pharmacy practice. B is incorrect because a 30-day continuity exception is not a standard legal provision; termination is legally immediate. C is incorrect because clinical relationships do not create implied continuation of a CPA; the formal legal instrument is required. D is incorrect because state board notification does not substitute for having a valid CPA and is insufficient basis for continued CPA activities.

Question 18

A CPA between a pharmacist and a cardiologist authorizes initiation and adjustment of anticoagulation therapy and related laboratory orders for patients with atrial fibrillation. A patient with both atrial fibrillation and critically high blood glucose presents. The pharmacist wants to initiate an insulin regimen. Which of the following best applies?

  1. The pharmacist may initiate insulin therapy because the CPA covers all drug therapy management for this patient.
  2. The pharmacist may initiate insulin therapy because addressing a critically high glucose level is an emergency.
  3. The pharmacist may initiate insulin therapy because diabetes management is a recognized pharmacist clinical competency.
  4. The pharmacist may not initiate insulin therapy as the CPA is limited to anticoagulation management. (correct answer)
Explanation: A CPA grants authority only within its defined scope. This CPA authorizes anticoagulation management for atrial fibrillation; it does not authorize management of other conditions. The pharmacist must refer the critical glucose finding to the physician or another appropriate provider. A is incorrect because the CPA covers anticoagulation therapy for a specific condition, not all drug therapy for any condition the patient has. B is incorrect because the CPA's scope does not expand due to clinical urgency; the pharmacist must refer this issue to a physician. C is incorrect because clinical competency does not create legal authority; the CPA defines the legal scope.

Question 19

A pharmacist and a physician in a state without a CPA enabling statute want to formalize a collaborative arrangement for anticoagulation therapy management. Which of the following best describes whether they may do so?

  1. They may create a CPA because physicians have broad authority to delegate clinical tasks to other professionals.
  2. They may create a CPA because anticoagulation management is a nationally recognized pharmacy clinical service.
  3. They may not create a CPA without a state statute authorizing collaborative practice agreements. (correct answer)
  4. They may create a CPA if the pharmacist holds a board certification in anticoagulation management.
Explanation: Without a state enabling statute, a CPA between a pharmacist and physician has no legal force to expand pharmacy practice. The enabling statute establishes the legal framework within which CPAs may grant authority. A is incorrect because a physician's delegative authority is bounded by state law; physician delegation alone cannot expand pharmacist authority where no enabling statute exists. B is incorrect because clinical recognition of a service does not create legal authority; the legal framework must exist first. D is incorrect because board certification does not create CPA authority in the absence of enabling legislation.

Question 20

A state requires that CPAs be filed with and accepted by the state board before becoming effective. A pharmacist and physician execute a CPA but have not yet filed it with the board. The pharmacist begins drug therapy management activities on the effective date written in the CPA. Which of the following best applies?

  1. The pharmacist may proceed because the CPA is legally complete upon signatures of both parties.
  2. The pharmacist may proceed because the board filing is a ministerial formality that does not affect the CPA's legal validity.
  3. The pharmacist may proceed during the 30-day window typically provided by state boards for registration of newly executed CPAs.
  4. The pharmacist may not proceed until the CPA is filed with and accepted by the state board. (correct answer)
Explanation: When state law requires CPA registration with the state board as a condition of effectiveness, the CPA does not become legally effective until that registration requirement is met. Performing CPA-authorized activities before the CPA is effective means practicing beyond legal scope without proper authority. A is incorrect because in states requiring board registration, signatures alone are insufficient; registration creates the legal effectiveness. B is incorrect because the filing requirement may be a substantive condition of CPA effectiveness, not merely a ministerial formality. C is incorrect because a universal 30-day registration window is not a standard provision across all states.